A Leader in Multiple Sclerosis
Since 2011, Sanofi Genzyme has rapidly emerged as a leader in multiple sclerosis (MS), an often disabling disease of the central nervous system affecting more than 2.3 million people worldwide.
MS is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath—the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.
Our personalized approach
We recognize that truly personalized medicine involves developing relationships with patients and caregivers, health care providers, and disease organizations and foundations.